# Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors

> **NCT01648465** · PHASE2 · TERMINATED · sponsor: **Hellenic Cooperative Oncology Group** · enrollment: 25 (actual)

## Conditions studied

- Gastrointestinal Tumors
- Pancreatic Tumors
- Gastrointestinal Neuroendocrine Tumors
- Pancreatic Neuroendocrine Tumors

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01648465
- **Lead sponsor:** Hellenic Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08-06
- **Primary completion:** 2017-01
- **Final completion:** 2019-08-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01648465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01648465, "Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01648465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*